Biogen (NASDAQ:BIIB) Price Target Raised to $191.00

Biogen (NASDAQ:BIIB) had its price target lifted by investment analysts at Wedbush from $187.00 to $191.00 in a research note issued to investors on Wednesday,MarketScreener reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. Wedbush’s target price indicates a potential upside of 4.04% from the company’s previous close.

BIIB has been the topic of several other research reports. Stifel Nicolaus increased their target price on Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Tudor Pickering set a $201.00 price target on Biogen in a research note on Monday, February 9th. Sanford C. Bernstein reissued a “market perform” rating on shares of Biogen in a research note on Monday, February 9th. Oppenheimer boosted their price objective on shares of Biogen from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Citigroup upped their target price on shares of Biogen from $185.00 to $215.00 and gave the company a “neutral” rating in a research note on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $207.96.

Biogen Stock Up 0.1%

Shares of BIIB opened at $183.58 on Wednesday. The business’s fifty day moving average price is $186.19 and its two-hundred day moving average price is $170.98. The firm has a market capitalization of $26.94 billion, a price-to-earnings ratio of 20.67, a PEG ratio of 1.49 and a beta of 0.15. Biogen has a 52 week low of $110.04 and a 52 week high of $202.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the previous year, the business posted $3.44 EPS. The company’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, analysts predict that Biogen will post 15.83 earnings per share for the current year.

Insider Buying and Selling at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider owned 8,043 shares in the company, valued at $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.18% of the company’s stock.

Institutional Investors Weigh In On Biogen

Institutional investors and hedge funds have recently bought and sold shares of the company. World Investment Advisors boosted its holdings in shares of Biogen by 4.9% in the 4th quarter. World Investment Advisors now owns 6,739 shares of the biotechnology company’s stock valued at $1,186,000 after purchasing an additional 317 shares in the last quarter. Corient Private Wealth LLC grew its holdings in Biogen by 18.0% during the 4th quarter. Corient Private Wealth LLC now owns 41,149 shares of the biotechnology company’s stock worth $7,245,000 after acquiring an additional 6,287 shares during the period. Hsbc Holdings PLC raised its position in shares of Biogen by 11.1% in the 4th quarter. Hsbc Holdings PLC now owns 503,832 shares of the biotechnology company’s stock worth $88,838,000 after acquiring an additional 50,314 shares in the last quarter. Pure Financial Advisors LLC acquired a new position in shares of Biogen in the 4th quarter valued at about $206,000. Finally, SHP Wealth Management acquired a new stake in Biogen in the fourth quarter worth $39,000. Institutional investors own 87.93% of the company’s stock.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Canaccord raised its price target on BIIB to $245 and reiterated a Buy rating, implying meaningful upside versus current levels — a bullish analyst signal that can support share gains. Canaccord raises BIIB PT to $245Article
• Positive Sentiment: FDA approved a higher‑dose SPINRAZA regimen, strengthening Biogen’s rare‑disease franchise and supporting longer‑term revenue potential from SMA treatments. FDA clears higher‑dose SPINRAZAArticle
• Neutral Sentiment: Biogen agreed to acquire Apellis for ~$5.6B in cash (plus potential contingent payments), adding commercial immunology and nephrology assets (SYFOVRE, EMPAVELI) that bolster growth strategy but require execution and integration. Biogen to buy Apellis for $5.6BArticle
• Neutral Sentiment: Market reaction: Apellis stock surged (big premium to APLS holders), validating the bid price, but the takeover effectively caps Apellis upside — an outcome analysts note while weighing Biogen’s strategic gain versus cash outlay. Apellis hits 2‑year high after Biogen dealArticle
• Negative Sentiment: A law firm launched an investor probe into the proposed Apellis sale, creating potential legal/transactional friction and additional uncertainty around deal process or pricing. Investor alert — probe into Apellis saleArticle
• Negative Sentiment: Several analysts remain cautious on Biogen (and some on Apellis), keeping Hold/neutral ratings and warning the deal may cap upside or not materially change near‑term catalysts — this analyst skepticism can weigh on BIIB near term. Analysts remain cautious despite positivesArticle

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.